MRK Merck & Co., Inc

0  0%
Previous Close 62.32
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 various presentations (5) at ASCO June 3-5, 2017. Abstracts 9014, 4515, 4503, 3012, 6010.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects
Januvia (Sitagliptin)
Type 2 Diabetes
Approved March 1, 2017.
Odactra (MK-8237)
House dust mite allergies
PDUFA date August 27, 2017 under priority review.
Urothelial Carcinoma
Phase 3 trial met primary endpoint - February 14, 2017.
Doravirine (MK-1439)
PDUFA date June 14, 2017.
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
Phase 3 data due 4Q 2017.
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Fully enrolled. Data due in 2019.
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016.
Cytomegalovirus (CMV) Infection
Phase 3 trial stopped due to lack of efficacy - February 14, 2017.
MK-8931 (017) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016.
Keytruda - KEYNOTE-045
Bladder Cancer
Phase 3 initiated June 2016. Initial data due 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
Type 2 diabetes
Phase 3 planned.
Epacadostat with Keytruda -
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Phase 3 planned.
Epacadostat with Keytruda -
Cancer - squamous cell carcinoma of the head and neck
Phase 3 data due mid-2017.
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
PDUFA date May 10, 2017. Priority review.
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 2b complete.
Chronic cough
Approval announced March 14, 2017.
Relapsed or Refractory Classical Hodgkin Lymphoma
PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data.
Microsatellite Instability-High Cancer
BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.
RENFLEXIS - SB2 (infliximab biosimilar)
Biosimilar candidate of Remicade
Priority review announced November 29, 2016. Approval announced March 23, 2017.
Metastatic Merkel cell carcinoma
PDUFA date May 27, 2017.

Latest News

  1. Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
  2. FDA approves 2nd near-copy of Remicade for immune disorders
  3. Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C
  4. 10 Reasons Merck Could Be the World's Most Perfect Stock
  5. The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria
  6. Merck Donates $300,000 to Support Neglected Tropical Disease Elimination Efforts in Africa
  7. Is J&J's Pharma Sales Slowdown a Warning for Other Players?
  8. Better Buy: Merck & Co. Inc. vs. Johnson & Johnson
  9. Merck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017
  10. Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
  11. Is the market overvalued?
  12. Dow 30 Stock Roundup: Microsoft Buys Cloud Tech Firm, Disney's "Beauty and the Beast"
  13. Bristol-Myers to license two drugs to Biogen, Roche
  14. Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops
  15. How US Drugmakers Profit From China's Biotech Boom
  16. Healthcare Sector Earnings: Making A Comeback In Q1 2017?
  17. Merck Stock History: The Drugmaker's Boom, Bust, and Bounce Back
  18. Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma
  19. Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
  20. Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?